We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Totally Resistant Tuberculosis Appears in India

By HospiMedica International staff writers
Posted on 30 Jan 2012
Four patients with tuberculosis (TB) resistant to five front-line drugs and seven second-line medications have been identified in India, making them virtually untreatable with available medications.

Researchers at PD Hinduja National Hospital and Medical Research Center (Mumbai, India) reported on the four patients, who were resistant to isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin--the standard first-line drugs--as well as ofloxacin moxifloxacin, kanamycin, amikacin, capreomycin, para-aminosalicylic acid, and ethionamide. More...
In three of the cases, the researchers conducted a careful analysis of their prescriptions and found that in an effort to cure their multidrug-resistant TB (MDR-TB), each had been given erratic, unsupervised second-line drugs, added individually and often in incorrect doses, from multiple private practitioners over an 18-month period.

As a result, the patients are now classified as more than extensively drug-resistant TB (XDR-TB), and have become totally drug-resistant TB (TDR-TB). These patients are the first in a series of 12 cases that have emerged since doctors at the institution began grappling with increasingly resistant strains of TB. The researchers blamed the rise of such resistance on India's healthcare system, which has had some success against normal TB, but which they said does not pay enough attention to resistant strains. As a result, many patients with resistant TB go to unqualified private physicians, resulting in inadequate care that leads to increasing resistance, rather than cure. The cases were reported in a letter published online on December 21, 2011, in Clinical Infectious Diseases.

“We must ensure treatment adherence to minimize interruption. We must also ensure the selection and use of appropriate drug regimens and rapid diagnostics so that people with drug resistant TB are started on the correct regimens at the right time,” said lead author Zarir Udwadia, MD.

The TB bacterium in most cases succumbs to a regimen consisting of isoniazid, rifampin, ethambutol, and pyrazinamide for eight weeks, followed by isoniazid and rifampin for another 18 weeks. But inadequate or interrupted treatment can lead to resistance; MDR-TB is resistant to isoniazid and rifampin, although other first-line drugs and several second-line drugs remain available. XDR-TB is resistant to isoniazid and rifampin, as well as any fluoroquinolone and at least one of three injectable second-line drugs, such as amikacin, kanamycin, or capreomycin.

Related Links:

PD Hinduja National Hospital and Medical Research Center


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.